Patient Preferences for the Disclosure of Prognosis After Esophagectomy for Cancer with Curative Intent
Sjoerd M. Lagarde(University of Amsterdam), J. Jan B. van Lanschot(Erasmus MC Cancer Institute), Ellen M.A. Smets(Amsterdam University Medical Centers), J.C.J.M. de Haes(University of Amsterdam), S. Franssen(Erasmus MC), T.C.K. Tran(Erasmus MC), Jochem R. van Werven(Amsterdam UMC Location University of Amsterdam), Hugo W. Tilanus(Amsterdam UMC Location University of Amsterdam), John Th. M. Plukker(University Medical Center Groningen)
Cited by 81
Related Papers
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
|JNCI Journal of the National Cancer Institute|1993|15.9k
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Extended Transthoracic Resection Compared with Limited Transhiatal Resection for Adenocarcinoma of the Esophagus
|New England Journal of Medicine|2002|1.6k
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
|Journal of Clinical Oncology|2021|795